{\rtf1\ansi\deff0\deftab360

{\fonttbl
{\f0\fswiss\fcharset0 Arial}
{\f1\froman\fcharset0 Times New Roman}
{\f2\fswiss\fcharset0 Verdana}
{\f3\froman\fcharset2 Symbol}
}

{\colortbl;
\red0\green0\blue0;
}

{\info
{\author Biblio 7.x}{\operator }{\title Biblio RTF Export}}

\f1\fs24
\paperw11907\paperh16839
\pgncont\pgndec\pgnstarts1\pgnrestart
Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation., Van Molle, Wim, Brusselmans Koen, Tesolin L., and Waeterloos Genevi\'e8ve , Modern Vaccines/adjuvants Formulation: Impact On Future Development, 17/5/2013, Issue Herriot,J.,  Vanden Bossche,G., Lausanne, Switserland, (2013)\par \par }